ARMATA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage of 100.00% for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-17.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage · last filed 2022-03-17
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, award vesting rights, percentage for the quarter ending 2021-03-31 was 100.00%, a 0.00% change year-over-year.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, award vesting rights, percentage for the quarter ending 2020-03-31 was 100.00%.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, award vesting rights, percentage for fiscal 2021 was 100.00%, a 0.00% change from fiscal 2020.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, award vesting rights, percentage for fiscal 2020 was 100.00%, a 0.00% change from fiscal 2019.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, award vesting rights, percentage for fiscal 2019 was 100.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 12 month |
|---|---|---|---|---|
| 2021-12-31 | 100.00% 10-K · filed 2022-03-17 | |||
| 2021-09-30 | 100.00% 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | 100.00% 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | 100.00% 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 100.00% 10-K · filed 2021-03-18 | |||
| 2020-09-30 | 100.00% 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | 100.00% 10-Q · filed 2020-08-13 | |||
| 2020-03-31 | 100.00% 10-Q · filed 2020-05-14 | |||
| 2019-12-31 | 100.00% 10-K · filed 2020-03-19 | |||
| 2019-09-30 | 100.00% 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | 100.00% 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |